Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Verano HoldingsVRNO +3.85%80 Equity-to-Asset is 0.40 as of Jun. 2026, which is 26% below its 10-year median of 0.54. GuruFocus rates VRNO with a GF Score™ of 80/100 and a GF Value™ of $6.58 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Verano Holdings ranks worse than 75.42% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Verano Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $676.5 Mil. Verano Holdings's Total Assets for the quarter that ended in Jun. 2026 was $1,699.2 Mil.
Therefore, Verano Holdings's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.40.
The historical rank and industry rank for Verano Holdings's Equity-to-Asset or its related term are showing as below:
VRNO'
s Equity-to-Asset Range Over the Past 10 Years
Min: -119 Med: 0.54 Max: 0.71
Current: 0.4
During the past 7 years, the highest Equity to Asset Ratio of Verano Holdings was 0.71. The lowest was -119.00. And the median was 0.54.
VRNO's Equity-to-Asset is ranked worse than 75.42% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs VRNO: 0.40
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Verano Holdings Equity-to-Asset Related Terms
Verano Holdings Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Verano Holdings's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Verano Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verano Holdings Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Verano Holdings's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Verano Holdings's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Verano Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verano Holdings (VRNO) has a Equity-to-Asset of 0.40 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Verano Holdings and its competitors. This is 26% below median its historical median of 0.54. According to the industry distribution chart, Verano Holdings ranks #758 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 75.4%.
Is Verano Holdings' Equity-to-Asset too high?
Verano Holdings' current Equity-to-Asset of 0.40 is 26% below median its 10-year median of 0.54. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Verano Holdings' value of 0.40 is 34.4% below this industry median. Based on the distribution chart, Verano Holdings ranks #758 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Verano Holdings has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Verano Holdings' Equity-to-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Verano Holdings ranks #758 out of 1005 companies for Equity-to-Asset. This places Verano Holdings in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Verano Holdings' value of 0.40 is 34.4% below this benchmark. While the company's 10-year median is 0.54 vs. the industry median of 0.61, Verano Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Verano Holdings's current Equity-to-Asset of 0.40 is 34.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Verano Holdings and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Verano Holdings's current Equity-to-Asset is 0.40, which is 26% below median its own 10-year median of 0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Verano Holdings stock overvalued right now?
Based on GuruFocus' analysis, Verano Holdings (VRNO) is currently considered Fairly Valued. The stock's GF Value™ is $6.58, compared to a current price of $6.21 — trading 5.6% below its estimated fair value. The current Equity-to-Asset is 0.40, which is 26% below median its 10-year median of 0.54 and 34.4% below the Drug Manufacturers industry median of 0.61. Verano Holdings' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Verano Holdings (VRNO), the current Equity-to-Asset is 0.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Verano Holdings (VRNO) Overvalued in 2026?
Based on GuruFocus' analysis, Verano Holdings stock appears to be undervalued.
The current stock price of $6.21 is trading 5.6% below its estimated GF Value™ of $6.58.
GuruFocus considers Verano Holdings to be Fairly Valued.
Key valuation signals for VRNO:
Equity-to-Asset: 0.40 (26% below median its 10-year median of 0.54)
GF Value™: $6.58 vs. price of $6.21 (5.6% below fair value)
Industry Position: 34.4% below the Drug Manufacturers median (#758 of 1005)
No single metric tells the full story. See the VRNO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Verano Holdings Corp is a vertically integrated, multi-state cannabis operator in the United States. The company operates through cultivation (wholesale) and retail segments. Its consumer brands include Encore, Avexia, MUV, Savvy, BITS, and Verano, while its retail dispensaries operate under brands such as Zen Leaf and MUV. The company derives the majority of its revenue from the retail segment.
80GF Score
Get the complete analysis for VRNO
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRNO has been successfully added to your 
